8-K: Theriva Biologics Doses First Patient in VIRAGE2 Pancreatic Cancer Trial

Theriva Biologics has dosed the first patient in its VIRAGE2 Phase 2a clinical trial, evaluating a more frequent dosing regimen for its VCN-01 therapy in metastatic pancreatic cancer.

Summary

• Theriva Biologics announced the dosing of the first patient in the VIRAGE2 Phase 2a clinical trial on August 6, 2026.
• This trial is a proof-of-concept study to evaluate more frequent, repeated dosing of VCN-01 (zabilugene almadenorepvec) in first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients.
• Patients in the trial are treated with standard-of-care gemcitabine/nab-paclitaxel chemotherapy.
• Enrollment is expected to be completed in the second half of 2026, with initial data anticipated by Q3 2027.
• The trial aims to inform the VCN-01 dosing regimen for a potential future pivotal Phase 3 trial.
• The VIRAGE2 trial builds on positive observations from the VIRAGE Phase 2b trial, where two doses of VCN-01 showed improved survival outcomes.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, marking a significant step in the clinical trial process for VCN-01, with potential for future efficacy.

Positives

• First patient dosed in the VIRAGE2 clinical trial, a key milestone.
• The trial is designed to refine the VCN-01 dosing regimen based on positive prior study data and regulatory feedback.
• Previous Phase 2b data showed improved overall survival, progression-free survival, and duration of response with VCN-01 combination therapy.
• Both EMA and FDA recognized improved survival with two doses of VCN-01 and suggested exploring more frequent dosing.
• VCN-01's mechanism of action targets tumor cells and degrades the tumor stroma, potentially enhancing co-administered therapies and immune response.
• VCN-01 has been administered to 143 patients across various trials and compassionate use programs.

Negatives

• The VIRAGE2 trial is a small, proof-of-concept study with only 6 evaluable patients.
• The study is not formally powered for evaluation of clinical efficacy endpoints.
• Completion of enrollment is pending, with initial data not expected until Q3 2027.
• The company's ability to raise capital and secure partnerships is critical for future development.

Risks

• The company's ability to finalize protocols for future clinical trials and obtain sufficient financing for planned trials remains a risk.
• Results from the VIRAGE2 trial may not support further clinical development or the benefits of more frequent repeated dosing.
• There is a risk that VCN-01 may not achieve regulatory approval for commercialization or meet ongoing regulatory requirements.
• Competitors' developments could render VCN-01 obsolete or non-competitive.
• The company's ability to maintain license agreements and its patent estate is subject to ongoing risks.
• The company's ability to remain well-financed is a persistent risk.

Future Outlook

Enrollment in the VIRAGE2 trial is expected to conclude in the second half of 2026, with initial pharmacodynamic and safety/tolerability data anticipated by the third quarter of 2027. The results will guide the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial.

Management Comments

• The first patient dosed in VIRAGE2 marks an important clinical development milestone as the evaluation of more frequent, repeated dosing is a critical step in the advancement of VCN-01 towards a potential pivotal Phase 3 clinical trial in metastatic PDAC patients.
• Our current clinical data indicate that repeated administration of VCN-01 to metastatic PDAC patients may significantly increase its tumor stroma-degrading effects and further enhance the antitumor immune response.
• A positive outcome from the VIRAGE2 trial will enable us to refine the design and dosing regimen of our proposed pivotal Phase 3 clinical trial in metastatic PDAC patients treated with SoC chemotherapy.
• Since the tumor stroma is a challenge for multiple classes of cancer therapies, a repeated VCN-01 dosing regimen may also improve outcomes when combined with other interventions such as immunotherapies, antibody-drug conjugates, KRAS inhibitors, and emerging targeted cancer treatments.

Industry Context

StockSavvy.ai notes that the advancement of VCN-01 into a more frequent dosing regimen trial aligns with industry trends focused on optimizing drug delivery and efficacy for challenging cancers like pancreatic ductal adenocarcinoma. The focus on tumor stroma degradation is a key area of research in oncology, aiming to overcome treatment resistance.

Stakeholder Impact

• Shareholders: Positive development in the clinical pipeline, potentially increasing the value of their investment if the trial is successful.
• Patients: Potential for improved treatment outcomes for metastatic pancreatic cancer patients if VCN-01 proves effective with the new dosing regimen.
• Healthcare Providers: May gain a new therapeutic option for treating metastatic PDAC.
• Regulatory Bodies (EMA, FDA): Will review data from the trial to assess the safety and efficacy of VCN-01 for future development.

Next Steps

• Complete enrollment in the VIRAGE2 trial in H2 2026.
• Anticipate initial pharmacodynamic and safety/tolerability data by Q3 2027.
• Use trial results to inform VCN-01 dosing regimen for a potential Phase 3 trial.
• Potentially combine VCN-01 with other interventions like immunotherapies, antibody-drug conjugates, KRAS inhibitors, and emerging targeted cancer treatments.

Key Dates

Recommendation

The announcement of dosing the first patient in a Phase 2a trial is a positive step, but it is early-stage and proof-of-concept. While prior data is encouraging, significant clinical and regulatory hurdles remain. The company's financial stability and ability to secure future funding are also key considerations. Therefore, a 'hold' recommendation is appropriate pending further data and de-risking events.

Keywords

VCN-01, Pancreatic Cancer, Metastatic PDAC, Clinical Trial, Oncolytic Virus, Theriva Biologics, Drug Dosing, Tumor Stroma